Certification Measures

Measures and Standards

Every QOPI Certified practice will be evaluated on both measures and standards.  ASCO's Quality Oncology Practice Initiative (QOPI®) gives you the quality measures that were  developed by world-renowned practicing oncologists and quality experts, using clinical guidelines and published standards, such as the National Initiative on Cancer Care Quality (NICCQ), ASCO/NCCN Quality Measures, and ASTRO/ASCO/AMA PCPI Oncology Measures. Standards and measures are continually re-assessed to maintain rigor.

Overall Quality Measures:

There are 26 measures that count toward the overall Quality Score. This score must be above the 75% threshold in order to be eligible to apply for Certification.  View more about the measures.

The QOPI Certification Site Assessment is the second component of the QOPI Certification Program, intended to review the concordance of a practice with structural quality standards. 

When a practice applies for Certification, their policies and procedures will be assessed against the Certification Safety Standards. Practices will be asked to submit documentation of their compliance with the Certification Standards and required to participate in an on-site review to assess their compliance. A practice must be compliant with all of the Certification Safety Standards before Certification can be awarded.

The Certification Standards are adapted from the ASCO/ONS chemotherapy safety standards and are intended to reduce the risk of errors when providing cancer patients with chemotherapy, and to provide a framework for best practices in cancer care. Specifically, they can inform practice policies and procedures, internal quality assessment, and external quality monitoring.

They address key areas of patient care including:

  • Staffing
  • Treatment Planning & Chart Documentation
  • Informed Consent
  • Chemotherapy Orders
  • Drug Preparation
  • Chemotherapy Administration
  • Patient Monitoring and Assessment
  • Preparedness for Emergencies
  • Oral Chemotherapy
  • Patient Education

History

Administration of antineoplastic agents is a complex process fraught with the potential for patient harm. Challenges to patient safety grow as the number of chemotherapeutic regimens expands and oral chemotherapy drugs become commonplace.

ASCO leaders envisioned that the ASCO/ONS safety standards would be appropriate to become the majority of the QOPI Certification site standards. When reviewing the full set of standards, those that met the following criteria were prioritized for inclusion in the QOPI Certification Program:

  • Standards that apply broadly to all types of  practices that would seek QOPI Certification
  • Standards most crucial for patient safety;
  • Standards that do not duplicate QOPI medical record measures.

Module

#

Measure

Core

1

Pathology report confirming malignancy*  

Core

2

Staging documented within one month of first office visit*                                               
NQF Endorsed #0386 (adapted)

Core

6

Pain addressed appropriately (defect-free measure, 3, 4a, and 5)*                                 
NQF Endorsed #0383 (adapted) 

Core

9

Documented plan for chemotherapy, including doses, route, and time intervals*

Core

10

Chemotherapy intent (curative vs. non-curative) documented before or within two weeks after administration*

Core

21a

Smoking status/tobacco use documented in past year *
NQF Endorsed #0028 (adapted)

Core

24

Patient emotional well-being assessed by the second office visit*

Symptom

27

Corticosteroids and serotonin antagonist prescribed with moderate/high emetic risk chemotherapy*

Symptom

33

Infertility risks discussed prior to chemotherapy with patients of reproductive age*

EOL

38

Pain addressed appropriately (defect-free measure, 35, 36a, and 37)*           
NQF Endorsed #0383/#0384 (adapted)

EOL

45a

Hospice enrollment and enrolled more than 7 days before death (defect-free measure, 42 and inverse 45)*
NQF Endorsed #0216 (adapted)        

Breast

53

Combination chemotherapy received within 4 months of diagnosis by women under 70 with AJCC stage I (T1c) to III ER/PR negative breast cancer**                                                                                                   
NQF Endorsed #0559 (adapted)

Breast

54

Test for Her-2/neu overexpression or gene amplification*                                       
NQF Endorsed #1878 (adapted)

Breast

56a

Trastuzumab not received when Her-2/neu is negative or undocumented (inverse of 56 )*
NQF Endorsed #1857 (adapted)

Breast

57

Trastuzumab received by patients with AJCC stage I (T1c) to III Her-2/neu positive breast cancer*
NQF Endorsed #1858 (adapted)

Breast

59

Tamoxifen or AI received within 1 year of diagnosis by patients with AJCC stage I (T1c) to III ER or PR positive breast cancer*                                                                                                                         
NQF Endorsed #0220/#0387 (adapted) 

Colorectal

66

CEA within 4 months of curative resection for colorectal cancer*

Colorectal

68

Adjuvant chemotherapy received within 4 months of diagnosis by patients with AJCC stage III colon cancer*
NQF Endorsed #0223/#0385 (adapted)

Colorectal

72

Adjuvant chemotherapy received within 9 months of diagnosis by patients with AJCC stage II or III rectal cancer*

Colorectal

73

Colonoscopy before or within 6 months of curative colorectal resection or completion of primary adjuvant chemotherapy*                                                                                                                                     
NQF Endorsed #0572 (adapted)

Colorectal

74

KRAS testing for patients with metastatic colorectal cancer who received anti-EGFR MoAb therapy*
NQF Endorsed #1859 (adapted)

Colorectal

75a

Anti-EGFR MoAb therapy not received by patients with KRAS mutation (Inverse of 75 )*
NQF Endorsed #1860 (adapted)

NSCLC

81

Adjuvant cisplatin-based chemotherapy received within 60 days after curative resection by patients with AJCC stage II or IIIA NSCLC*

NSCLC

84

Performance status documented for patients with initial AJCC stage IV or distant metastatic NSCLC*

NSCLC

85

Platinum doublet first-line chemotherapy or EGFR-TKI (or other targeted therapy with documented DNA mutation) received by patients with initial AJCC stage IV or distant metastatic NSCLC with performance status of 0-1 without prior history of chemotherapy*

NSCLC

88

Positive  mutation for patients with stage IV NSCLC who received first-line EGFR tyrosine kinase inhibitor or other targeted therapy*